iShares Genomics Immunology and Healthcare ETF

    $IDNA · BlackRock · tracks NYSE FactSet Global Genomics and Immuno Biopharma Index · since 2019

    Dividend yield

    0.14%

    Expense ratio

    0.47%

    Assets

    $0.2B

    Weighted P/E

    26.4x

    About IDNA

    Invests in companies advancing genomic medicine, immunotherapy, and bioengineering. IDNA combines large biotech leaders with smaller innovators across gene editing, mRNA, and cell therapy.

    Top holdings

    Vertex Pharmaceuticals$VRTXRegeneron Pharmaceuticals$REGNModerna Inc.$MRNAIllumina Inc.$ILMNBioNTech SE$BNTXCRISPR Therapeutics$CRSPBeam Therapeutics$BEAMIntellia Therapeutics$NTLAExact Sciences$EXASBioMarin Pharmaceutical$BMRN

    Sector exposure

    • Biotechnology64.8%
    • Pharmaceuticals18.4%
    • Life Sciences Tools12.6%
    • Healthcare Equipment3.4%
    • Other0.8%

    How StockWorthy analyses IDNA

    ETFs hold companies rather than generating cash flow themselves, so IDNA is assessed on cost, income and the valuation of what it owns: the expense ratio, the current yield against its own 0.18% long-run average, and a holdings-weighted P/E and growth rate built from the underlying positions. Figures are educational and not investment advice.

    Sign in to see live pricing, yield history and the full holdings breakdown, or browse all ETFs.